our locations in europe n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Our Locations in Europe PowerPoint Presentation
Download Presentation
Our Locations in Europe

Loading in 2 Seconds...

play fullscreen
1 / 22

Our Locations in Europe - PowerPoint PPT Presentation


  • 101 Views
  • Uploaded on

Our Locations in Europe. Headquarters Affiliates Plant sites. Dublin. London. Amsterdam. Brussels. Pfaffenhofen. Paris. Altkirch. Vienna. Munich. Zurich. Madrid. Rome. Lisbon. Istanbul. European Production Sites. Altkirch , France. Pfaffenhofen, Germany.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Our Locations in Europe' - lola


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
our locations in europe
Our Locations in Europe

Headquarters

Affiliates

Plant sites

Dublin

London

Amsterdam

Brussels

Pfaffenhofen

Paris

Altkirch

Vienna

Munich

Zurich

Madrid

Rome

Lisbon

Istanbul

european production sites
European Production Sites

Altkirch, France

Pfaffenhofen, Germany

facts and figures of our pfaffenhofen plant
Facts and Figures of Our Pfaffenhofen Plant
  • Pharmaceutical manufacturing activities established at the current site as part of Luitpold-Werk in 1962
  • Additional state-of-the-art facilities for solids manufacturing/packaging inaugurated in 2007
  • Only DAIICHI SANKYO plant in Europe producing bulk and finished pharmaceutical goods
  • Approved by local and international authorities such as the U.S. FDA
  • Approximately 70 per cent of DAIICHI SANKYO EUROPE’s turnover is produced or handled via the Pfaffenhofen plant
  • Toll manufacturing for USA and Asian markets
  • Successful development and launch site for new products, such as OLMETEC PLUS®, SEVIKAR®/AZOR®, and CS-8635
sales of global products
Sales of Global Products

Exchange rates: (FY 2008) ¥143.5=€1 / (FY 2009) ¥131.2=€1

These figures do not include out-licensing sales.

efient
EFIENT®

Potential blockbuster in cardiovascular care

Antiplatelet agent to prevent atherothrombotic events

Discovered by DAIICHI SANKYO and its Japanese research partner Ube Industries, co-developed and co-promoted with Eli Lilly and Company

European launch sequence started in Spring 2009

Key contributor to company sales over the next years

the olmesartan success story
The Olmesartan Success Story

Leading angiotensin receptor blocker (ARB) with excellent blood pressure lowering efficacy

Launched in 2002 as 7th product in the ARB market, still showing high growth rates

OLMETEC® launched in 58 countries worldwide*, including the majority of European markets

Co-marketing agreements with Menarini Group, Pfizer, Nycomed

OLMETEC PLUS® launched in majority of European countries, launch sequence for additionaldosage comprising 40 milligrams olmesartan startedin Spring 2010

SEVIKAR® launched in several European countriesin 2009

Singel pill combination containing olmesartan, hydrochlorotiazide and amlodipine in approval process

*As of February 2010

sevikar
SEVIKAR®

Fixed dose combination of olmesartan and amlodipine

Significantly lowers blood pressure and was well tolerated in clinical trials

Effective treatment option: Most hypertensive patients need two or more medications to normalise their blood pressure

Approval for majority of European countries achieved, launch started in January 2009

In the U.S. the combination was already approved in September 2007 under the name of AZOR®, sales have been successful since launch in October 2007

r d expenditures in the fiscal year 2009
R&D Expenditures in the Fiscal Year 2009

€1.5 billion

20.7% of net sales

Creating first-in-class, best-in-class, high-value-added products

KazunoriHirokawa

Head of R&D Division

DAIICHI SANKYO EUROPE GmbH

daiichi sankyo is investing heavily into r d
DAIICHI SANKYO is Investing Heavily into R&D

Percentage of net sales

21.9%

21.4%

20.7%

18.5%

18.3%

* Forecast

the global r d network
The Global R&D Network

DAIICHI SANKYO R&D

~ 1,500 people

Pharmaceuticaltechnology

~400 People

AsubioPharma

~ 300 people

DAIICHI SANKYO RD Associe

~150 people

DAIICHI SANKYO DEVELOPMENT (London)

~ 50 people

DAIICHI SANKYO

(Edison, NJ)

~300 people

Luitpold Pharmaceuticals

(Shirley, NY)

~40 people

DAIICHI SANKYO EUROPE (Munich)

~130 people

U3 Pharma

(Munich)

~28 people

Asia, South & Central America

~80 people

Ranbaxy

Laboratories

~1,400 people

As of 31 March 2010

the european r d network
The European R&D Network

DAIICHI SANKYOEUROPE GmbH Munich

130 people(development, pharmaceuticaltechnology)

DAIICHI SANKYODEVELOPMENT LTD.London

50 people(development)

U3 Pharma GmbH Martinsried

28 people

(research)

As of 31 March 2010

r d highlights
R&D Highlights
  • Invention of the statin class
  • Invention of insulin sensitizer class (TZDs)
  • Invention of the oral factor Xa class
  • Leading quinolones (levofloxacin, ofloxacin)
  • Best-in-class angiotensin II receptor blocker (olmesartan)
  • Standard colon cancer treatment developed (irinotecan)

DAIICHI SANKYO invents and develops globally leading products

development of factor xa inhibitor edoxaban
Development of Factor Xa Inhibitor Edoxaban

Edoxaban is a direct factor Xa inhibitor and a member of a new class of oral anticoagulants.

It is given once daily and has been investigated in phase II trials in patients undergoing orthopedic surgery and in patients with atrial fibrillation.

It is developed solely by DAIICHI SANKYO as a new treatment for the prevention of both arterial and venous thromboembolism.

Edoxaban is tested in two phase III clinical studies

ENGAGE AF-TIMI 48 with about 16,500 patients focuses on prevention of thromboembolic stroke in atrial fibrillation.

HOKUSAI-VTE with about 7,500 patients focuses on the treatment and recurrence-prevention of venous thromboembolism.

key projects from our development pipeline
Key Projects fromour Development Pipeline

*Only developed in Japan / **Only developed in the US / As of March 2010

acknowledged research pipeline
Acknowledged Research Pipeline
  • Renowned R&D Directions magazine selected DAIICHI SANKYO in 2009 to have the “Best Cardiovascular Pipeline”
  • Great potential of EFIENT® and edoxaban acknowledged
  • More than 25 years experience with anticoagulants and anti-thrombotics